Equities

Neogenomics Inc

Neogenomics Inc

Actions
  • Price (EUR)14.40
  • Today's Change0.20 / 1.41%
  • Shares traded--
  • 1 Year change-7.10%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments415438515
Total Receivables, Net131122114
Total Inventory242423
Prepaid expenses181512
Other current assets, total8.206.1817
Total current assets597605682
Property, plant & equipment, net184199212
Goodwill, net523523527
Intangibles, net373408442
Long term investments----0
Note receivable - long term00.030.24
Other long term assets4.745.086.93
Total assets1,6811,7401,870
LIABILITIES
Accounts payable202118
Accrued expenses746263
Notes payable/short-term debt000
Current portion long-term debt/capital leases00.071.14
Other current liabilities, total2.137.565.19
Total current liabilities969087
Total long term debt538535533
Total debt538535534
Deferred income tax243555
Minority interest------
Other liabilities, total818286
Total liabilities740742762
SHAREHOLDERS EQUITY
Common stock0.130.130.12
Additional paid-in capital1,1901,1611,124
Retained earnings (accumulated deficit)(247)(159)(15)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(1.67)(3.9)(0.64)
Total equity9429981,108
Total liabilities & shareholders' equity1,6811,7401,870
Total common shares outstanding127127124
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.